NCT07188844 - An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

DRUG

Batoclimab

Batoclimab 340 mg SC QW

Trial Locations (30)

3000

Site Number - 4680, Leuven

11000

Site Number - 8501, Belgrade

20132

Site Number - 6307, Milan

28207

Site Number - 1610, Charlotte

32174

Site Number - 1617, Ormond Beach

40139

Site Number - 6305, Bologna

40356

Site Number - 1611, Nicholasville

41110

Site Number - 6347, Larissa

78759

Site Number - 1601, Austin

300736

Site Number - 8403, Timișoara

900591

Site Number - 8400, Constanța

06519

Site Number - 1621, New Haven

S2000BZL

Site Number - 7753, Rosario

S2000DTP

Site Number - 7751, Rosario

C1199ABB

Site Number - 7750, Buenos Aires

T4000AXL

Site Number - 7752, San Miguel de Tucumán

70200-730

Site Number - 9103, Brasília

81210-310

Site Number - 9101, Curitiba

14048-900

Site Number - 9100, Ribeirão Preto

04103

Site Number - 6702, Leipzig

265 04

Site Number - 6341, Pátrai

115 25

Site Number - 6344, Athens

00133

Site Number - 6309, Rome

61-731

Site Number - 3207, Poznan

30-688

Site Number - 3208, Krakow

31-202

Site Number - 3209, Krakow

20-064

Site Number - 3210, Lublin

20-701

Site Number - 3206, Lublin

40-123

Site Number - 3201, Katowice

081 81

Site Number - 8603, Prešov